Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Affiliations

• ¹ Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, and Comprehensive Cancer Center, Vienna, Austria.
• ² Peter MacCallum Cancer Center, and Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.
• ³ Clinic I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
• ⁴ Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, University of Kansas, Kansas City, KS.
• ⁵ Department of Oncology, Oslo University Hospital, Oslo, Norway.
• ⁶ Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute, Emory University, Atlanta, GA.
• ⁷ James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH.
• ⁸ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
• ⁹ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
• ¹⁰ Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX.
• ¹¹ Maisonneuve-Rosement Hospital, University of Montreal, Montreal, QC, Canada.
• ¹² Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW, Australia.
• ¹³ Department of Medicine II, University of Würzburg Medical Center, University of Würzburg, Würzburg, Germany.
• ¹⁴ Department of Laboratory Medicine and Department of Medicine Huddinge, Karolinska Institute and University Hospital, Stockholm, Sweden.
• ¹⁵ Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
• ¹⁶ Memorial Sloan Kettering Cancer Center, New York, NY.
• ¹⁷ Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
• ¹⁸ Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
• ¹⁹ Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
• ²⁰ Division of Hematology-Oncology, Bone Marrow and Stem Cell Transplantation Service, Weill Cornell Medicine, Cornell University, New York, NY.
• ²¹ Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
• ²² Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
• ²³ Blood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.
• ²⁴ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD.
• ²⁵ Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
• ²⁶ Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.
• ²⁷ Novartis Pharmaceuticals, Basel, Switzerland.
• ²⁸ Novartis Pharmaceuticals, East Hanover, NJ; and.
• ²⁹ Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, University of Chicago, Chicago, IL.